Uncategorized

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has unveiled the results of its Hexvix® Phase III clinical trial in China.

New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria.

Astria Therapeutics, Inc. announced the pricing of an underwritten offering of 8,253,895 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock, and to certain investors in lieu of common stock who so choose, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares

EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.

Immetas Therapeutics and GC Biopharma announced that they have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases.

Scholar Rock Holding Corporation, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share.

SystImmune, Inc announced that the first patient was treated on October 10th, 2023 with BL-B01D1, a first-in-class bispecific antibody-drug conjugate targeting both EGFR and HER3, as part of the global, multi-center Phase 1 study, BL-B01D1-LUNG-101, that is underway to evaluate the safety, tolerability, and efficacy of BL-B01D1 in individuals with Metastatic or Unresectable Non-Small Cell

AstraZeneca announced eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden.

The publication in ACS Catalysis , one of the world’s most influential scientific journals, compares the four best performing enzymes for PET degradation under industrial conditions and confirms the superior performance of Carbios’ enzyme Carbios proposes an international standardized method for enzyme comparison thereby confirming its position as the world leader of enzymatic PET depolymerization

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced that it will participate at two upcoming investor conferences.